MedPath

FDA Approves Opzelura as First Topical JAK Inhibitor for Atopic Dermatitis

• Incyte's Opzelura (ruxolitinib) cream has received FDA approval as the first topical JAK inhibitor for treating atopic dermatitis in adolescents and adults who failed other topical therapies.

• Clinical trials demonstrated significant efficacy with 51-54% of patients achieving treatment success at week 8, compared to 8-15% in control groups.

• Despite its topical application, Opzelura carries a boxed warning for serious infections and cardiovascular risks, potentially impacting its projected $1 billion peak sales potential.

The US Food and Drug Administration has approved Incyte's Opzelura (ruxolitinib) cream for treating atopic dermatitis, marking a significant milestone as the first topical Janus kinase (JAK) inhibitor to receive regulatory clearance in the United States.
The novel treatment, approved for adolescents and adults whose symptoms are inadequately controlled by other topical prescription therapies, represents a new approach to managing this chronic inflammatory skin condition. However, the approval comes with important safety considerations that could influence its market trajectory.

Safety Considerations and Market Impact

Despite its topical administration route, Opzelura has not escaped the FDA's class-wide safety concerns for JAK inhibitors. The drug carries a boxed warning highlighting risks of serious infections and increased likelihood of heart attack, stroke, or cardiac death. These warnings emerged following an FDA safety review primarily focused on Pfizer's oral JAK inhibitor Xeljanz.
The safety requirements led to a three-month delay in Opzelura's approval and may affect its commercial potential. Prior to these developments, analysts had projected peak sales of $1 billion in the US market alone, particularly considering its potential expansion into vitiligo treatment.

Clinical Trial Results Demonstrate Efficacy

The FDA's approval was supported by compelling data from two pivotal studies, TRuE-AD 1 and TRuE-AD 2. In these trials, Opzelura demonstrated superior efficacy compared to non-medicated cream:
  • TRuE-AD1: 53.8% of patients achieved treatment success versus 15.1% in the control group
  • TRuE-AD2: 51.3% of patients reached treatment success compared to 7.6% in the control group
The drug also showed significant improvement in itch reduction, with approximately 51-52% of treated patients achieving a clinically meaningful reduction in itch severity, compared to 15-16% in the control groups.

Addressing Unmet Medical Needs

"It can be hard for people to fully appreciate how difficult AD can be and the tremendous impact it has on patients," said Julie Block, president and CEO of the National Eczema Association. "The chronic itch is difficult to cope with and related sleep issues can be exhausting. Many patients and their dermatologists are looking for additional options to meet current unmet needs in the management of AD."

Competitive Landscape

Opzelura's approval positions it ahead of several oral JAK inhibitors seeking approval for atopic dermatitis, including:
  • Pfizer's Cibinqo (abrocitinib), already approved in the UK
  • Eli Lilly's Olumiant (baricitinib)
  • AbbVie's Rinvoq (upadacitinib)

Future Prospects

Beyond atopic dermatitis, Incyte is pursuing an expanded indication for Opzelura in vitiligo. Following successful phase 3 trials (TRuE-V1 and TRuE-V2), the company plans to submit regulatory applications for this additional indication in both the US and Europe by year-end.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Dermatology Advances: Approvals, Trial Results, and New Guidelines Emerge

The FDA approved bimekizumab for moderate-to-severe hidradenitis suppurativa, marking the first treatment targeting both IL-17A and IL-17F cytokines.
Subcutaneous nivolumab's PDUFA date was updated, based on Phase 3 data demonstrating noninferiority to intravenous nivolumab in renal cell carcinoma.

FDA Accepts LEO Pharma's Delgocitinib Cream NDA for Chronic Hand Eczema

The FDA has accepted LEO Pharma's New Drug Application (NDA) for delgocitinib cream 2% for treating moderate to severe Chronic Hand Eczema (CHE) in adults.
The NDA is supported by Phase 3 DELTA 1 and DELTA 2 clinical trials, which demonstrated the efficacy and safety of delgocitinib cream compared to a cream vehicle.

Aclaris Therapeutics Initiates Phase IIa Trial of ATI-2138 for Atopic Dermatitis

Aclaris Therapeutics has dosed the first subject in a Phase IIa clinical trial evaluating ATI-2138 for moderate to severe atopic dermatitis.
The open-label trial will assess the safety, tolerability, pharmacokinetics, and efficacy of ATI-2138 over a 12-week period in approximately 15 patients.

FDA Approves Lebrikizumab (Ebglyss) for Moderate-to-Severe Atopic Dermatitis

The FDA has approved lebrikizumab (Ebglyss) for treating moderate-to-severe atopic dermatitis in adults and children 12 years and older who weigh at least 88 pounds.
Approval was based on the ADvocate 1, ADvocate 2, and ADhere trials, which showed significant itch relief and skin clearance, sometimes as early as 2-4 weeks.

FDA Approves Eli Lilly's Ebglyss (lebrikizumab) for Eczema Treatment in Adults and Children

The FDA has approved Eli Lilly's Ebglyss (lebrikizumab) for treating moderate-to-severe eczema in adults and children aged 12 and older.
Ebglyss, a monoclonal antibody targeting the IL-13 protein, offers a new first-line biologic option when topical treatments are insufficient.

FDA Approves Lebrikizumab (Ebglyss) for Moderate-to-Severe Atopic Dermatitis in Patients 12 and Older

The FDA has approved lebrikizumab (Ebglyss), an interleukin-13 inhibitor, for treating moderate-to-severe atopic dermatitis in patients aged 12 and older.
Clinical trials (ADvocate 1, ADvocate 2, and ADhere) demonstrated that lebrikizumab, alone or with topical corticosteroids, significantly improved skin clearance compared to placebo.

FDA Approves Lilly's Ebglyss (lebrikizumab-lbkz) for Atopic Dermatitis Treatment

The FDA has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for treating moderate-to-severe atopic dermatitis (eczema) in patients 12 years and older.
Ebglyss, a targeted IL-13 inhibitor, is administered as a monthly injection after an initial treatment phase to reduce eczema inflammation.

FDA Approves Eli Lilly's Eczema Drug

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's drug for the treatment of eczema, offering a new therapeutic option for patients.
This approval marks a significant advancement in dermatological treatments, potentially improving the quality of life for individuals suffering from eczema.

FDA Approves Leqselvi (Deuruxolitinib) for Severe Alopecia Areata

The FDA has approved Leqselvi (deuruxolitinib) 8 mg tablets for treating adults with severe alopecia areata, offering a new oral option.
Clinical trials (THRIVE-AA1 and THRIVE-AA2) showed that over 30% of patients achieved 80% or more scalp hair coverage after 24 weeks.

FDA Approves Epsolay for Inflammatory Lesions of Rosacea

The FDA has approved Epsolay, a 5% encapsulated benzoyl peroxide cream, for treating inflammatory lesions of rosacea in adults.
Clinical trials showed Epsolay reduced inflammatory lesions by nearly 70% after 12 weeks, compared to 38-46% with the vehicle cream.

Reference News

[1]
Incyte leads JAK push into eczema as FDA clears Opzelura cream
pharmaphorum.com · Jan 11, 2025
[2]
Incyte leads JAK push into eczema as FDA clears Opzelura cream
pharmaphorum.com · Sep 21, 2021
[3]
AbbVie's Rinvoq cleared in EU for atopic dermatitis
pharmaphorum.com · Apr 1, 2025
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy